| Tawnya J Stewart, | |
|
2924 Knight St Ste 369, Shreveport, LA 71105-2413 | |
| (318) 210-0587 | |
| Not Available |
| Full Name | Tawnya J Stewart |
|---|---|
| Gender | Female |
| Speciality | Clinical Social Worker |
| Experience | 12 Years |
| Location | 2924 Knight St Ste 369, Shreveport, Louisiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457649881 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 14998 (Louisiana) | Primary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Brentwood Acquisition-shreveport Inc | 1951379312 | 15 |
News Archive
Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two major patent issuances covering tumor-targeted gene delivery and precision-targeted cancer immunotherapy, respectively.
The United States Patent Office has issued a patent to Dr. Mark DeCoster, associate professor of biomedical engineering at Louisiana Tech University, for his invention of an "Electromagnetic Probe Device" - an innovative technology developed at Louisiana Tech's Institute for Micromanufacturing.
Stem cells that respond after a severe injury in the lungs of mice may be a source of rapidly dividing cells that lead to lung cancer, according to a team of American and British researchers.
As U.S. President Barack Obama continues his official visit to Africa—with a stop Friday in Pretoria, South Africa to meet with President Jacob Zuma—advocates from AIDS Healthcare Foundation, the African Council of AIDS Service Organizations and South African AIDS patients will host a press conference in Pretoria, Friday, June 28th from 10:00am to 11:00am at the Sheraton Pretoria.
An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia (ALL) cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study. It will be presented at the 47th annual meeting of the American Society of Clinical Oncology in Chicago June 3-7.
› Verified 8 days ago
| Entity Name | Brentwood Acquisition-shreveport Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164725701 PECOS PAC ID: 1951379312 Enrollment ID: O20040923000015 |
News Archive
Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two major patent issuances covering tumor-targeted gene delivery and precision-targeted cancer immunotherapy, respectively.
The United States Patent Office has issued a patent to Dr. Mark DeCoster, associate professor of biomedical engineering at Louisiana Tech University, for his invention of an "Electromagnetic Probe Device" - an innovative technology developed at Louisiana Tech's Institute for Micromanufacturing.
Stem cells that respond after a severe injury in the lungs of mice may be a source of rapidly dividing cells that lead to lung cancer, according to a team of American and British researchers.
As U.S. President Barack Obama continues his official visit to Africa—with a stop Friday in Pretoria, South Africa to meet with President Jacob Zuma—advocates from AIDS Healthcare Foundation, the African Council of AIDS Service Organizations and South African AIDS patients will host a press conference in Pretoria, Friday, June 28th from 10:00am to 11:00am at the Sheraton Pretoria.
An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia (ALL) cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study. It will be presented at the 47th annual meeting of the American Society of Clinical Oncology in Chicago June 3-7.
› Verified 8 days ago
| Entity Name | Finding A Better Me |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467979708 PECOS PAC ID: 8224363585 Enrollment ID: O20190710000649 |
News Archive
Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two major patent issuances covering tumor-targeted gene delivery and precision-targeted cancer immunotherapy, respectively.
The United States Patent Office has issued a patent to Dr. Mark DeCoster, associate professor of biomedical engineering at Louisiana Tech University, for his invention of an "Electromagnetic Probe Device" - an innovative technology developed at Louisiana Tech's Institute for Micromanufacturing.
Stem cells that respond after a severe injury in the lungs of mice may be a source of rapidly dividing cells that lead to lung cancer, according to a team of American and British researchers.
As U.S. President Barack Obama continues his official visit to Africa—with a stop Friday in Pretoria, South Africa to meet with President Jacob Zuma—advocates from AIDS Healthcare Foundation, the African Council of AIDS Service Organizations and South African AIDS patients will host a press conference in Pretoria, Friday, June 28th from 10:00am to 11:00am at the Sheraton Pretoria.
An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia (ALL) cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study. It will be presented at the 47th annual meeting of the American Society of Clinical Oncology in Chicago June 3-7.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tawnya J Stewart, 2924 Knight St Ste 369, Shreveport, LA 71105-2413 Ph: (318) 210-0587 | Tawnya J Stewart, 2924 Knight St Ste 369, Shreveport, LA 71105-2413 Ph: (318) 210-0587 |
News Archive
Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two major patent issuances covering tumor-targeted gene delivery and precision-targeted cancer immunotherapy, respectively.
The United States Patent Office has issued a patent to Dr. Mark DeCoster, associate professor of biomedical engineering at Louisiana Tech University, for his invention of an "Electromagnetic Probe Device" - an innovative technology developed at Louisiana Tech's Institute for Micromanufacturing.
Stem cells that respond after a severe injury in the lungs of mice may be a source of rapidly dividing cells that lead to lung cancer, according to a team of American and British researchers.
As U.S. President Barack Obama continues his official visit to Africa—with a stop Friday in Pretoria, South Africa to meet with President Jacob Zuma—advocates from AIDS Healthcare Foundation, the African Council of AIDS Service Organizations and South African AIDS patients will host a press conference in Pretoria, Friday, June 28th from 10:00am to 11:00am at the Sheraton Pretoria.
An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia (ALL) cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study. It will be presented at the 47th annual meeting of the American Society of Clinical Oncology in Chicago June 3-7.
› Verified 8 days ago
Karl Reichter, LICSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 510 E Stoner Ave, Shreveport, LA 71101 Phone: 319-990-4401 | |
Mrs. Chelsey Vincent, LMSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 856 Texas Ave, Shreveport, LA 71101 Phone: 318-429-6938 | |
Kemeco Taylor-small, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 510 E Stoner Ave, Shreveport, LA 71101 Phone: 318-221-8411 Fax: 318-990-5599 | |
Mr. Dock Voorhies, SOCIAL WORKER Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 510 E Stoner Ave, Shreveport, LA 71101 Phone: 318-424-6040 Fax: 318-424-6121 | |
Danielle Bailey, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 4111 Pines Rd Unit 65, Shreveport, LA 71119 Phone: 318-613-0147 | |
Charles Lee, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 6654 Gilbert Pl, Shreveport, LA 71106 Phone: 318-865-4360 | |
Mr. Andrew Wilson, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 6007 Financial Plz Ste 213, Shreveport, LA 71129 Phone: 318-458-5158 Fax: 318-220-8108 |